

# Index

## A

- ABC transporters
  - export of cholesterol, 103–104, 104f
  - membrane topology, 103, 103f
- Acetyl-CoA carboxylase (ACC), 30–31, 30f, 31f, 32, 39, 56, 56f
- Acute promyelocytic leukemia (APL), 259–260, 259f
- Acyl coenzyme A: cholesterol acetyltransferases (ACATs), 102
- ADAM proteins, 372–373
- Adaptive thermogenesis
  - signaling through  $\beta$ -adrenergic receptors, 28, 85–86, 86f
  - uncoupling protein UCP1, 27–29, 28t
- Adenosine nucleotide translocator (ANT), 307–309, 308f
- Adherens junctions, 123, 124, 124t
- Adipose tissue
  - hormonal signals, 25, 25t
  - pro-inflammatory signals, 48
  - regulation of metabolism by nuclear receptors, 75–77, 76f
  - role in energy balance, 24
  - stromal vascular fraction, 47
- Adventitia, 107, 108f
- Aggresomes, 424–425
- Agouti-related protein (AgRP), 36–37, 36f
- Akt/PKB
  - activation mechanism, 54–56, 55f
  - as an insulin effector, 56, 56f
  - regulation of glucose metabolism, 48–49, 49f
  - regulation of HKII-VDAC binding, 309
  - regulation of TORC2 gene expression, 83–85, 84f
  - survival signaling, 80–81, 80f
- Allostery, 8
- $\alpha$ -lytic protease, metastable states, 348
- $\alpha$ -synuclein, 336t, 337
  - dopamine metabolism, 405
  - oxidative damage, 405–406
  - pesticides, 405
  - structure and function, 402t, 403f, 404
  - toxicity, 404–405
- Alzheimer, Alois, 369
- Alzheimer's disease, 14, 14t, 369–370
  - amyloid cascade hypothesis, 370
  - cholinergic hypothesis, 369–370
  - disease progression, 370, 371f
- Amino acid availability
  - class III PI3Ks, 292f, 296
  - Rag GTPases, 292f, 296
- AMP-activated protein kinase (AMPK)
  - signaling
    - AMPK activation mechanism, 33–35, 35f
    - AMP/ATP ratio, 33–35, 35f
    - upstream kinases, 33–35
  - AMPK structure and function, 33–35, 34f, 35f
  - gating of the mTOR cassette, 292f, 292
  - intracellular energy regulation, 31–33, 32f
    - in adipose tissue, 32f, 33
    - in the hypothalamus, 39, 39f
    - in liver, 32f, 33
    - in skeletal muscle, 32, 32f
  - SIRT1-regulated FA oxidation, 87–88, 88f
- AMPA receptors
  - and Alzheimer's disease, 377–379, 378f
  - in LTP and LTD, 377–378, 378f
- Amylin, 347t
- Amyloid  $\beta$  (A $\beta$ ) metabolism
  - degradation by NEP and IDE, 374, 374f
  - export by LRP, 373–374, 374f
  - generation from APP, 370–373, 372f
  - import by RAGE, 373–374, 374f
- Amyloid  $\beta$  (A $\beta$ ) protein
  - abnormal function

- Amyloid  $\beta$  (A $\beta$ ) protein (*cont.*)  
 fibrillization and toxicity, 375–376  
 impaired LTD, 377–379  
 metal cations (heavy metals), 376  
 normal function, 376–377  
 structure and folding, 375–376, 375f
- Amyloid diseases, 12–15  
 AA amyloidosis, 13, 14t  
 Alzheimer's disease, *see* Alzheimer's disease  
 amyotrophic lateral sclerosis, *see*  
 Amyotrophic lateral sclerosis  
 dialysis-related amyloidosis, 14t  
 heavy-chain amyloidosis, 14t  
 islet amyloid polypeptide (IAPP), 14, 14t  
 light-chain amyloidosis, 13–14, 14t  
 Parkinson's disease, *see* Parkinson's disease  
 polyglutamine repeat disorders, *see*  
 Polyglutamine repeat disorders  
 Prion diseases, *see* Prion diseases  
 transthyretin (TTR) amyloidosis, 14t
- Amyloid fibrils, 13
- Amyloid precursor protein (APP)  
 $\alpha$ -secretase (ADAM), 370–373, 372f  
 $\beta$ -secretase (BACE1), 370–373, 372f  
 $\gamma$ -secretase complex and Presenilins,  
 370–373, 372f
- Amyotrophic lateral sclerosis (ALS), 14t, 431  
 astrocytes and microglia, 444–446  
 disease progression, 443–444, 444f  
 impaired fast axonal transport, 442–443
- Anaphase-promoting complex/cyclosome,  
 184, 184t  
 Cdc20 and Cdh1 adapters, 189, 196–197  
 degradation and exit from mitosis, 196  
 structure and function, 188–189
- Anfinsen, Christian, 348, 349
- Angiogenic switch, 314  
 VEGF, 314
- Apolipoproteins, 99–102, 100t, 101f
- Apoptosis, 227  
 regulation by p53, 236  
 signaling pathways, 228–229, 228f
- Apoptosome, 229
- Arcuate nucleus, 36, 36f
- ARF, in senescence, 237–238
- Arginase, 1, 162
- Arginine methyltransferases, 255–256, 256t
- Argonaute proteins, 262–263, 263f  
 structure and function, 262–264, 263f
- Arterial wall, 107–108, 108f
- AS160, 56, 56f
- Astrocytes, 145, 145t, 379–380  
 Alzheimer's disease, 380–384, 383f  
 end feet, synaptic monitoring, 383  
 neuroinflammatory actions, 382–384, 383f
- Ataxin-1, 433
- Ataxin-3, 447
- ATF6 signaling, 401, 402–403, 402f  
 processing, 404
- Atherosclerosis, 5, 107  
 biophysics of disturbed blood flow,  
 110–111, 111t, 111f  
 disease progression, 108f  
 oxLDL and inflammation, 113–114  
 rupture, 126–128, 126f
- ATM/ATR proteins  
 in G1/S pathway, 202–203  
 in Intra-S and G2/M pathways, 206–207  
 structure and function, 210–212, 211f
- ATP-sensitive potassium channels  
 insulin secretion  
 inward rectification, 66  
 sensitivity to metabolites, 66  
 structure, 65, 65f
- Autoimmune disorders, 142–143, 142t
- Autophagy, 298–300, 391  
 decision complex, 299–300, 300f  
 autophagy proteins, 299–300, 300f  
 beclin, 299–300, 300f  
 class III PI3Ks, 299–300, 300f  
 transport to aggresomes and IBs, 424–426,  
 426f  
 HDAC6, 425–426, 426f  
 Hsf1, 425–426  
 Hsp90, 425–426  
 p97/VCP, 425–426, 426f
- B**
- BACE1 protein, 373
- Bacterial lipopolysaccharides (LPS), 131, 139
- Bad protein, 230–231, 230t  
 regulation by Akt, 80–81, 80f
- Banting, Fred, 4
- Barriers, oncogenic  
 central role of p53 and pRb, 180, 180f  
 in response to Ras and c-Myc, 179–180  
 three layers of protection, 182
- Base excision repair (BER)  
 DNA damage, 201, 214–215, 215t  
 repair enzymes, 216
- Bcl2 proteins, 229, 230–232, 231t  
 Bax subfamily, 230, 230t  
 in B-cell lymphomas, 232  
 Bcl2 subfamily, 230, 230t

- BH3 only subfamily, 230–231, 230t, 231t
  - in release of cytochrome c, 232–233
  - as sensors, 230–231
  - subfamilies, 230, 230t
- Beclin-1 protein
  - role in autophagy, 298–300, 300f
  - structure and function, 299, 299f
- $\beta$ -adrenergic receptors, in adaptive thermogenesis, 85–86, 86f
- $\beta$ -catenin
  - in the EMT, 319–320
  - in Wnt signaling, 318–319, 318f
- $\beta$ -cell failure, in T2D, 46–47, 47f, 66–67, 347
- $\beta$ -2 microglobulin
  - domain swapping, 346
  - energy landscape, 344–345, 345f
  - fibrillization, 346
  - metal cations, 345
  - structure and function, 344–345, 345f
- $\beta$ -oxidation in muscle cells
  - feedback regulation, 30, 30f
  - regulation by AMPK, 30–31, 31f
  - steps in the process, 29–30, 29f
- Bell's equation, 120–121, 121f
- Bernard, Claude, 3–4
- Best, Charles, 4
- Bid protein, 231
- Bistability, 191f, 195
- Bloch, Felix, 8
- Block, Konrad, 6
- Blood-brain barrier, 35–36, 373–374, 380
- Blood flow
  - disturbed shear stresses, 110–111, 111f
  - endothelial sensing and responses, 112–113, 126
  - parabolic, 109–110, 109f
  - rate and velocity, 110
- Bmi1 oncoprotein, 254, 254t
- Bond lifetimes, 120–121, 121f
- Bone metastasis, Microenvironment, 338
  - RANK/RANKL signaling pathway, 338
  - release of TGF $\beta$ , 338
- Bone morphogenic proteins, *see* Transforming growth factor- $\beta$  (TGF- $\beta$ ) pathway
- Bragg, William Henry and Lawrence, 7
- Breast cancer associated proteins BRCA1, 2, 213–214, 213t, 214f
- Bromodomains, 257, 257t, 257f
- Brown adipose tissue
  - adaptive thermogenesis, 27–29
  - signaling through  $\beta$ -adrenergic receptors, 28, 85–86, 86f
  - uncoupling protein UCP1, 27–29, 28f
- C**
- Cadherins
  - in adherens junctions, 123, 124t
  - in diapédesis, 125
  - E-cadherin activity and the EMT
    - loss of E-cadherin function, 328–329
    - repression of E-cadherin transcription, 328f, 329–330, 330f
  - types and binding, 116
- Caloric restriction, 86–87
- cAMP-responsive element binding (CREB) protein, 83–85, 84f, 85–86, 86f
- Cancer stem cells, 331
- Cannon, Walter, 4
- Cardiac myocytes
  - NOS enzymes, 162–163, 162f
  - xanthine oxidoreductase, 167
- Cardiolipin, 232
- Carnitine palmitoyltransferase 1, 2 (CPT1, 2), 30, 31, 32, 39
- Caspases, 229–230
  - effectors, 229
  - initiators, 229
- Catalase, 157, 157f
- Catch bonds, 119–121, 121f
- Catecholamine signal transduction, 85–86, 86f
- Catenins
  - in adherens junctions, 123, 124t
  - in Wnt signaling, 326–327, 327f
- Caveolae
  - caveolins and eNOS, 112–113
- Cdc25 proteins, 184, 185t
- Cell adhesion molecules, Ig-SF
  - in diapédesis, 125
  - in PECAM-1 complexes, 124, 124t
  - in tight junctions, 123, 124t
  - types, ligands and expression, 116t, 117
- Cell cycle
  - activators and inhibitors, 184–185, 185t, 187, 195f, 196
  - cyclin/cyclin-dependent kinases, 183, 183t
    - at the G1/S transition, 182
    - at the G2/M transition, 187–188
  - E3 ubiquitin ligases, 183–184, 184t
    - anaphase-promoting complex/cyclosome, 184, 184t, 196–197
    - SCF complexes, 184, 184t, 187, 196
  - feedback loops, 194–195
  - mathematical models, 189–192
    - Goldbeter model, 192–194
    - Michaelis-Menton equation, 191–193, 191f

- Cell cycle (*cont.*)  
  multisite phosphorylation, 196  
  phases, 182–183, 183f
- Cell Cycle checkpoints, *see* Checkpoint pathways
- Changeux, John-Pierre, 8
- Chaperonins, 392, 392t  
  co-chaperones, 392t  
  type I (Hsp60), 392, 392t  
  type II (TriC/CCT), 392, 392t
- Charcot, Jean-Martin, 431
- Checkpoint kinases  
  in G1/S pathway, 202–203, 203f  
  in Intra-S and G2/M pathways, 204f, 206–207  
  structure and function, 210–212, 212f
- Checkpoint mediators  
  of ATM signals, 205–206  
  of ATR signals, 206  
  special structural properties, 213–214, 213t
- Checkpoint pathways, 206  
  G1/S checkpoint pathway, *see* G1/S checkpoint pathway  
  G2/M checkpoint pathway, *see* Intra-S phase and G2/M checkpoint pathway  
  intra-S phase checkpoint pathway, *see* intra-S phase and G2/M checkpoint pathway
- Checkpoint termination, 221–222
- Chemokines, 116–117, 123  
  in regulation of monocytes/macrophage migration, 147  
  SDF-1/CXCR4 axis, 315f, 316–318, 317f
- Chevreal, Michael, 6
- Cholesterol, 6, 91  
  role in membrane biophysics, 91–94, 92f, 93f, 94t  
  synthesis  
    HMGR-CoA, 95, *See also* HMGR-CoA insigs, 94–95, 94f, 96, 96f  
    SREBPs, 95–97, *See also* SREBPs transport, *see* Lipoproteins
- Cholesterol ester, 102–103
- Cholesterol ester transfer proteins (CETP), 102–103, 104f
- Chromatin modifying enzymes, 77
- Chromatin structure  
  epigenetic marks, 251–252, 251f  
  euchromatin, 250, 250f  
  heterochromatin, 250, 250f  
  histone tails, 251  
  recognition modules, 256–258
- Chromodomains, 256, 257t
- Chylomicrons, 99, 99t, 100, 100t, 102
- Ciechanover, Aaron, 9
- CIP/KIP, 184, 185t
- c-Myc  
  in cellular proliferation, 287–288, 288f  
  E-boxes, 285  
  in growth factor signaling, 273, 273f  
  in growth pathways, 286–287  
  inhibition by TGF- $\beta$ , 325–326, 325f  
  regulation by phosphorylation and ubiquitination, 285–286, 285t  
  RNAP I and RNAPIII gene expression, 286–287, 287f  
  structure and function, 286–287, 287f
- Cohen, Stanley, 4
- Collip, James, 4
- Commoner, Townsend, and Pake, 155
- Compton, Arthur, 7
- Conformational diseases, 14–15
- Congo red, 13
- Constitutive androgen receptor (CAR), 72, 72t, 74–75, 75f
- CpG islands, 253
- Creatine kinase, 165, 166f
- Cristae (mitochondrial), remodeling, 232–233
- c-Src  
  signaling roles, 322–323, 324f  
  structure and function, 319f, 320–322
- Cyclin/cyclin-dependent kinases, 183, 183t, 184, 186–187, 186f  
  *See also* Cell cycle
- Cystic fibrosis, CFTR protein, 347t, 349
- Cytochrome b<sub>558</sub>, 158
- Cytochrome c  
  in the intrinsic pathway, 228  
  sequestration and release, 232–233
- Cytokines, discovered and named, 4, 5
- Cytostatic drugs, 283–284
- D**
- Dale, Henry, 12
- Death domain (FADD, TRADD) proteins, 138
- Death-inducing signaling complex (DISC), 228, 231
- Dedifferentiation, 332
- Derlin-1 protein, 447
- Diabetes mellitus, *see* Type 2 diabetes
- Diabetic complications, 67
- Dialysis-related amyloidosis, 354–356
- Diapedesis, by monocytes, 125–126
- Dicer, 260f, 262–264, 263f  
  structure and function, 156–158, 157f

- Diels, O., 6
- Diffusion, lateral, along DNA, 217–218
- DISC, 138
- DJ-1
- oxidative damage, 421–422
  - structure and function, 413f, 418–419, 418f
- DNA damage, causes, 201
- DNA damage repair
- double-strand breaks
    - homologous recombination (HR), *see* Homologous recombination
    - non-homologous end joining (NHEJ), *see* Non-homologous end joining
  - single-strand breaks
    - base excision repair (BER), *see* Base excision repair
    - mismatch repair, *see* Mismatch repair
    - nucleotide excision repair (NER), *see* Nucleotide excision repair
- DNA damage, repair pathway, 202
- DNA methylation
- CpG islands, 253
  - hypermethylated genes and cancer, 253, 253t
- DNA sliding clamps, 207–208
- E**
- E1 activating enzymes, *see* Protein ubiquitination
- E2 conjugating enzymes, *see* Protein ubiquitination
- E2F transcription factors, 185–187, 186t, 186f
- in heterochromatin formation, 241–243, 243f
  - pocket protein binding, 185–186
  - in senescence, 236–237, 236f
- E3 ligating enzymes, *see* Protein ubiquitination
- E-boxes, 285
- Electron transport chain
- Chance and Williams model, 171
  - generation of ROS, 172
  - regulation by NO, 169
  - structure and function, 170f, 171–172
- Endocrine pancreas, Hormonal signals, 21–22
- Endothelial cells, 107–108, 108f
- cell-to-cell junctions
    - adherens junctions, 123, 124, 124t
    - nectin-afadin system, 124, 124t
    - PECAM-1 complexes, 124, 124t
    - tight junctions, 123–124, 124t
  - mechanotransduction, 112–113
- Endothelial surface layer, 112
- Energy balance, maintenance
- central nervous system, 20
  - fed and fast states, 19
  - hypothalamus and negative feedback, 20
    - See also* Hypothalamic feeding circuits
  - metabolic overload, 48–50
  - peripheral organs, 19
- Energy landscapes, 349–351, 350f
- in  $\beta$ -2 microglobulin, 354–356, 356f
- Epidermal growth factor family (EGF, Erbs), 273t, 274, 315, 316
- ErbB2 active form, 274
  - mutations in cancer, 277t, 283
- Epigenetic marks, 251–252, 251f
- recognition modules, 256–258
- Epigenetics
- gene silencing and cancer, 259–260
  - hallmark of cancer, 249–250
  - heritable changes, 249
  - transient modifications, 249
- Epithelial-to-mesenchymal transition, 313, 321–322
- E-cadherin transcription repression, 328f, 329–330, 330f
  - loss of E-cadherin function, 328–329
    - $\beta$ -catenin and Wnt signaling, 328
    - mediated by TGF- $\beta$ , 328
- ERAD, 401, 404–407
- in ALS, 447
  - in Huntington's disease, 447
  - p97/VCP motor protein, 405–407, 405f, 406f
  - sec61 translocon, 404, 404f
- ERK5 module, 279, 279f
- ERK module, 278, 279f
- Ernst, Richard, 8
- ER stress response chaperones, 394, 403
- Euchromatin, 250, 252
- Ewing, James, 11
- Exchangeable apolipoproteins, *see* Apolipoproteins
- Excitation-contraction coupling, 164–166
- contractile apparatus and forces, 167–168, 168f
  - phosphotransfer network, 165–166, 166f
  - regulation by NO and calcium, 167–168, 168f
  - role of myocytes, myofibrils, 165
- Excitotoxicity, 169
- Extrinsic pathway, *see* Apoptosis
- EZH2 histone methyltransferase, 254, 254t

**F**

- FAK, 318, 319  
 structure and function, 311–312, 319f
- Farnesoid X receptor (FXR), 72t, 97
- Fatty acid, cholesterol biosynthesis, 97, 403
- Feedback regulation (loops)  
 negative, *see* Negative feedback  
 positive, *see* Positive feedback
- Fenton reaction, 157, 157f, 160  
 in JNK signaling, 139
- Fibroblast growth factor family (FGF), 273t, 274, 315
- Fibroblasts, 11  
 in the arterial wall, 108f  
 carcinoma-associated fibroblasts (CAFs), 314, 315f  
 differentiation, 149  
 myofibroblasts, 149  
 roles in invasion and intravasation, 316  
 stellate cells, *see* Hepatic stellate cells  
 in tissue repair, 149
- Fibrotic diseases, 149
- Fibrous cap, in atherosclerosis  
 development of the cap, 126, 126f  
 inflammation, apoptosis in rupture, 126–128, 126f  
 role of matrix metalloproteinases, 127
- Fischer, Edmond, 9
- Focal adhesion complexes  
 c-Src, 318–320  
 integrins and cadherins, 318  
 in metastatic migration, 318–320  
 in SDF-1/CXCR4 signaling, 317–318, 317f  
 signaling complexes, 319–320, 319f
- Folkman, Judah, 11, 180–181
- FOXO proteins  
 in caloric restriction, 86  
 in gluconeogenesis, 83–85, 84f  
 regulation by Akt, 81, 81f  
 regulation by TGF- $\beta$ , 322–323, 324f  
 structure and function, 80–81, 81f
- Frank-Starlings law, 164, 164f
- Free cholesterol (FC) form, 102–103
- Friedman, Jeffrey, 25
- Furchgott, Robert, 155
- FUS protein, 449

**G**

- G1/S checkpoint pathway  
 activated by double-strand breaks, 202  
 checkpoint kinases, 209, 210f  
 p53/p21 node, 210–211, 212f  
 pathway components, ATM kinase, 209, 210f

 $\gamma$ -H2AX

- in checkpoint activation, 199–200  
 in checkpoint termination, 216
- $\gamma$ -secretases  
 in APP processing, 360–363, 362f  
 in Notch processing, 324–325, 324f
- Gastrointestinal tract  
 cholecystokinin, 26–27, 27t  
 glucagon-like peptide 1, 26–27, 27t  
 hormonal and peptide signals, 26–27, 27t
- Gerschman, Rebeca, 155
- Ghrelin  
 satiation signals, 26–27  
 secretion by A cells in the stomach, 26, 27t  
 signaling in the hypothalamus, 39–40, 39f, 40f
- Gilman, Alfred G., 7, 9
- Glucagon  
 secretion by  $\alpha$ -cells, 21t, 22  
 signaling in the liver, 22–24, 23f  
 glycogen synthase shuttle, 23, 23f  
 at the transcriptional level, 24  
 signal transduction, 83–85, 84f
- Glucocorticoids, 72t  
 in inhibition of inflammation, 142–143
- Glucogenesis, 3
- Gluconeogenesis, 22–23  
 in the liver, 83–85
- Glutamergic receptors, 377–379, 378f  
*See also* AMPA receptors; mGluRs;  
 NMDA receptors
- Glutaredoxin system, 161
- Glutathione peroxidase, 157, 161
- GLUT transporters, 22, 22t  
 GLUT2, glycolytic shift, 307–309, 308f  
 GLUT4 transport  
 pore formation, 56–57  
 role of AS160, 58, 58f  
 transport coordination by Rab GTPases, 57–58
- Glycocalyx, 112
- Glycogenolysis, 22
- Glycogen synthase kinase-3 (GSK3), 23, 23f, 49, 49f, 56, 56f  
 in c-Myc actions, 284–285  
 in Wnt signaling, 328, 328f
- Glycolytic shift, 291, 307–309, 308f
- Goldbeter model, 192–194
- G-protein-coupled receptors, 7
- Ground substance, 149
- Growth factor signaling, 271–273, 272f, 273t
- GTPase molecular switches, 57, 57f

**H**

- Hallmarks of cancer, 180–181, 237, 248–249, 271, 291, 314
- Hanahan, Douglas, 10, 180
- Harman, Denham, 155
- Hayflick, Leonard, 234
- Hayflick limit, 234
- Heat repeats, 208–209, 209f, 434
- Heat shock factor 1 (HSF1), 396–397
- Heavy metals, *see* Metal cations
- Hedgehog signaling
  - pathway in *Drosophila*, 335–336, 336f
  - pathway in mammals, 336–338, 337f
  - role in metastasis, 332–333
- hEmi1, 184, 185t
- Hepatic stellate cells, 149
- Hepatocyte growth factor (HGF) family, 273t, 274, 315t
- Hershko, Avram, 9
- Heterochromatin, 250–252
- Heterochromatin (adapter) protein 1 (HP1), 250, 258
  - in SAHFs, 241–242, 242t, 243f
- Heterochromatin formation
  - in senescence
    - E2F gene silencing, 243–244, 244f
    - role of pRb, 243–244
  - senescence-associated heterochromatin foci (SAHFs), 241–242, 242t, 243f
- Hexokinases, 49
  - glucokinase, 308
  - in glucose metabolism, 308
  - hexokinase II (HKII), 307–309, 308f
- High density lipoproteins (HDLs), 99, 99t, 100, 100t, 101, 104, 104f
- High-mobility group A (HMGA) proteins, 242, 242t, 243f
- Himsworth, Harold, 45
- Histone acetyltransferases (HATs), 254–255, 255t
  - P300/CBP, 252, 255t
  - tip60, 252, 255t
- Histone deacetylases (HDACs), 252, 253, 255, 255t
- Histone methylation and demethylation, 252, 255–256
- HMGR-CoA
  - cholesterol-lower drugs, 95
  - structure, 95, 95f
- Hodgkin, Dorothy, 8
- Homologous recombination, 201, 214, 215t
- Hormones, discovery of, 3–4
- Hsp60 chaperones, *see* Chaperonins
- Hsp70 chaperones, 392–394, 394f
  - co-chaperones, 392, 392t, 393, 403
  - Hsp70-related proteins (Hsp110, Grp170), 392t, 393–394
  - structure and function, 393–394, 394f, 395, 396f
- Hsp90 chaperones, 394–396
  - co-chaperones, 392t, 395–396, 395f, 396f
  - in regulation of HSF1, 396
  - structure and function, 394–395, 395f
- HtrA2/Omi
  - misfolded proteins, 420–421
  - structure and function, 413f, 420–421, 421f
- Huntingtin (Htt) protein, 431
  - aggregates, 436–438, 438f
  - and BDNF, 436
  - calcium homeostasis, 435
  - fast axonal transport, 436
  - and HAP1 and HIP1, 436
  - postsynaptic terminals, 435
  - presynaptic terminals, 434–435
  - structure and function, 434
- Huntington's disease, 14, 431
  - disease progression, 437–438, 438f
  - impaired fast axonal transport, 436
  - impaired transcription, 439–440
  - impaired UPS, 438–439
- Hyaluronan, 149
- Hydrogen peroxide
  - generation by superoxide dismutase, 156–157, 157f
  - oxidation of SH groups on cysteines
    - Cdc25, 160
    - protein tyrosine phosphatases, 159–161, 160f
    - PTEN, 159–161, 160f
  - regulation by thioredoxin, 161, 161f
  - as a signaling molecule, 156–157
- Hypothalamic feeding circuits
  - arcuate nucleus, 36–37, 36f
  - central network, 35–37, 36f
  - entry of hormones and metabolites, 35–36
  - regulation by leptin, 37–39
- Hypoxia
  - regulation of cellular growth, 294f, 295–296
    - HIF-1 gene expression, 295
    - S6K and 4E-BP1, 296–297
    - tumor stroma, 293–294
- Hypoxia-inducible factors (HIFs)
  - in regulation of metabolism and the glycolytic shift, 306–307
  - regulates c-Myc, 306–307

- Hypoxia-inducible factors (*cont.*)  
 regulates cytochrome oxidase, 307  
 upregulation of PDK1, 306  
 regulation by the PHD proteins, 305–306, 305f  
 regulation by pVHL, 305–306, 305f  
 structure and function, 304–306, 305f
- Hysteresis, 191f, 195
- I**
- Ignarro, Louis, 155
- IL-1/Toll signaling pathway, 131, 139
- Immortalization, 236
- Inclusion bodies, 424–425
- Induced pluripotent stem (iPS) cells, 266–267  
 dedifferentiation, 266  
 transdifferentiation, 266
- Inflammation, 4–5  
 biphasic character, 146–147  
 disease states, 131  
 fibroblasts, *see* Fibroblasts  
 interferon and hematopoietin signaling, 147  
 macrophages, *see* Macrophages  
 stem cells, *see* Stem cells
- Ink4 locus, 184, 185t
- Insulin, 4  
 regulation of glucose metabolism, 48–49, 49f  
 secretion by  $\beta$ -cells, 21–22, 21t  
 signaling in the liver, 22–24, 23f  
 glycogen synthase shuttle, 23, 23f  
 at the transcriptional level, 24  
 uptake of glucose by GLUTs, 22, 22t
- Insulin and insulin-like signaling pathway  
 Akt signaling node, 56–58, 56f  
 insulin receptor, 50–51  
 insulin receptor substrate (IRS) proteins, 51–52, 52f  
 phosphoinositide-3-OH kinase (PI3K)  
 class I PI3Ks, 52–54, 53f, 54f  
 phospholipid second messengers, 52–53  
 PTEN lipid phosphatase, 54, 54f  
 as survival signal, 80–81  
 TOR cassette, 58–60
- Insulin resistance  
 in liver, 60–62  
 FFA-TRL4 signaling, 60–61, 61f  
 inactivation of IRS proteins, 61–62, 61f  
 inflammatory signaling to NF- $\kappa$ B and JNK, 60, 61f  
 in muscle, 62–63  
 metabolic mismatches, 62  
 SOCS proteins, 63
- Insulin secretion by Islet  $\beta$ -cells  
 chain of events, 63–64, 64f  
 GLUT2-mediated transport, 63–64  
 role of ion channels, 64–65
- Integrins  
 in diapedesis, 125  
 in firm arrest, 125  
 in mechanotransduction, 122–123  
 receptor cooperativity, 316–317, 320–322, 321f  
 regulation of monocytes/macrophage migration, 147–148  
 structure and states, 121–123, 122f  
 types and roles, 115–116
- Intermediate density lipoproteins (IDLs), 99, 99t, 100, 100t
- Internal secretions, 3
- Intima, 107, 108f
- Intra-S phase and G2/M checkpoint pathway  
 chromatin subcompartments, 203  
 IRIFs and ATM activation, 203, 204f, 205  
 actions by ATM Mediators, 205–206  
 checkpoint kinases, 206  
 MRN complex, 203  
 SDSCs and ATR activation, 204f, 207–208  
 9-1-1 complex, 207–208  
 actions by ATR mediators, 208  
 ATR-ATRIP complex, 208  
 checkpoint kinases, 208
- Intrinsic pathway, *see* Apoptosis
- IRE1, 447
- IRE1 signaling, 401, 402–403, 402f  
 Hac1/XBP1 transcription factor, 402–403
- IR-induced foci (IRIFs), 203, 204f, 205
- Islet amyloid polypeptide  
 IAPP, 47  
 IAPP amyloid deposits, 66–67
- Islet  $\beta$ -cell failure, 66–67
- J**
- Jacob, Francois, 8
- JNK signaling pathway, 137, 137f, 279, 279f  
 effect of ROS (hydrogen peroxide), 138–139  
 Fenton reactions, 139
- K**
- Kendrew, John, 7
- Kennedy's disease, 433
- Kennedy's lipostatic hypothesis, 20

Krebs, Edwin, 9  
Kupffer cells, 147–148

## L

Langerhans, Paul, 3  
Lauterbur, Paul, 8  
Law of mass action, 190  
Lecithin: cholesterol acetyltransferase (LCAT), 102, 104f  
Leptin  
  in the Jak-STAT pathway, 38  
  in the PI3K pathway, 38  
  secretion by adipocytes, 25, 25t  
  signaling in the hypothalamus, 37–39, 38f  
  structure and function, 37–38, 37f  
Leptin resistance, 62–63  
Leukocyte migration  
  diapedesis, 125–126  
  firm arrest, 121–123  
  multiphase process, 117–118, 117f  
  role of slip and catch bonds, 119–121  
  tethering and rolling, 118–119, 119f  
Lewy bodies, 347, 411–412, 416  
Lewy, Friedrich, 411  
Limit cycle, 194, 194f  
Lipoproteins  
  apolipoproteins, 99–102, 99t, 100t, 101f  
  free fatty acid and cholesterol packaging, 98–99  
Liver  
  regulation of gluconeogenesis, 83–85  
  regulation of metabolism by nuclear receptors, 75–77, 76f  
  role in energy balance, 19, 22–24  
  signaling by glucagon and insulin, 22–24, 23f  
Liver fibrosis, 149  
Liver X receptor (LXR), 72, 72t  
LKB1 upstream kinase, 33–34  
  in SIRT1-regulated FA oxidation, 87–88, 88f  
Loewi, Otto, 12  
Long-term depression (LTD), 377–378, 378f  
Long-term potentiation (LTP), 377–378  
Lou Gehrig's disease, *see* Amyotrophic lateral sclerosis  
Low density lipoproteins (LDLs), 99, 99t, 100, 100t, 101f  
  oxidized, in atherosclerosis, 113–114  
LRRK2  
  mutated protein, 419–420  
  structure and function, 413f, 419–421, 420f  
LTD, in Alzheimer's disease, 376–377, 378f

Lynen, Feodor, 6  
Lysine demethylases, 255–256, 256t  
Lysine methyltransferases, 255–256, 256t

## M

MacKinnon, Roderick, 8  
MacLeod, J.J.R., 4  
Macrophages, 11  
  blood monocyte migration, 147–148  
  differentiation, 147–148  
  Kupffer cells, *see* Kupffer cells  
  M1 (classical) states, 147–148  
  M2 (alternative) states, 147–148  
  microglia, *see* Microglia  
  regulation by metabolism by nuclear receptors, 75–77, 76f  
  role in invasion and intravasation, 316–317  
  tumor-associated macrophages (TAMs), 315, 315f  
Macrophages/ monocytes, In the arterial wall, 108f  
Mad cow disease, *see* Prion diseases  
Mad protein, 284–285, 284f  
  *See also* c-Myc  
Magnetic resonance imaging, 8  
Mansfield, Peter, 8  
Matrix metalloproteinases  
  role in rupture of the fibrous cap, 127–128  
  types, 127, 127t  
Maturation-promoting factor (MPF), 192–194  
Max Perutz, 437  
Max protein, 284f, 284–285  
  *See also* c-Myc  
Mdm2, in regulation of p53, 238, 238f  
Mechanotransduction pathways  
  endothelial caveolae - nitric oxide, 112–113  
  endothelial lining and the cytoskeleton, 112  
  by receptors, adhesion molecules, ion channels, 126  
Media, arterial wall, 107, 108f  
Membrane lipid phases  
  biophysical properties, 92–93, 94t  
  gel and liquid phases, 91–92  
  phase diagrams, 93, 93f  
Membrane lipids  
  phases, *see* Membrane lipid phases  
  saturated and unsaturated, 92  
  structure, 92, 92f  
Mesenchymal-to-epithelial transition, 314, 331–332  
Mesenchymal stem cells, 150  
  in tissue engineering and repair, 150  
Metabolic syndrome, 45–46

- Metal cations, 15  
 in DNA damage, 213  
 protein folding and neurodegeneration, 345, 364, 422
- Metastasis, 10–11, 180–181, 180f  
 metastatic cycle, 330, 330f  
 metastatic spread, 332–333  
 roles of accessory cells, (15, 1), 306f  
 steps in the process, 315
- MGLURs, LTD and Alzheimer's disease, 377–379, 378f
- Michaelis-Menton equation, 190–192, 191f
- Microenvironment, 10–11  
 cellular composition, 145–146, 145t  
 fibroblasts, *see* Fibroblasts  
 macrophages, *see* Macrophages  
 stem cells, *see* Stem cells  
 in rupture of the fibrous cap, 126–128, 126f
- Microglia, 145–146, 145t  
 in Alzheimer's disease, 380–384, 383f  
 inflammatory cytokines, 380–384, 383f  
 NOS enzymes, 381  
 phagocytic actions, 381–382  
 poly (ADP-ribose) polymerase (PARP), 382
- MicroRNAs (miRNAs), 260f, 261–262  
 circuitry of proteins and miRs, 329, 329f, 330  
 in iPS cell maintenance, 266–267  
 oncomirs and tumor suppressors, 264–265  
 in regulation of E-cadherin expression, 329–330, 329f, 330f, 331
- Microtubule organizing center, 424
- Microvilli, 125
- Milieu intérieur*, 3
- Mismatch repair (MMR)  
 DNA damage, 201, 216
- MutS/MSH2-MSH6  
 lateral diffusion, 217–218  
 structure, 217, 217f  
 repair steps and enzymes, 216–217
- Mitogen activated protein (MAP) kinase  
 cassette, 272, 272f  
 and c-Myc, 284–285, 284f  
 as dynamical circuits, 280–281, 281f  
 bistability, 280  
 ultrasensitivity, 280  
 growth, stress and inflammatory signals, 279–280, 279f  
 inactive conformations, 281–282, 282f  
 mammalian families, 279–280, 279f  
 oocyte maturation circuit, 280–281, 281f  
 Raf MAPKKK, 272, 272f
- Molecular chaperones, 392–395, 399–401
- Moncada, Salvador, 155
- Monod, Jacques, 8
- Moore, Stannford, 348
- MRN (Mre11-Rad50-Nbs1) complex  
 in checkpoint pathways, 203–205  
 in DSB repair pathway, 219t, 220–221  
 structure and function, 213–214, 213t, 220–221, 221f
- mTOR cassette, 292–293, 292f  
 hypoxia link, 293–295, 294f  
 regulation by amino acid availability, 295–296  
 regulation by energy status, 293  
 regulation of translation initiation, 296–298, 297t, 298f  
 three components  
 mTOR, *see* TOR complexes  
 Rheb GTPase, 58–59, 59f  
 TSC complex, *see* Tuberous sclerosis complex
- Multisite phosphorylation  
 in the cell cycle, 196  
 in p53, senescence, 241, 241f
- Murad, Ferid, 155
- Muscle, Regulation of metabolism by nuclear receptors, 75–77, 76f
- Mutations, in cancer, 9–10, 236, 291, 292f, 303  
 in Bcl-2 in B-cell lymphomas, 232  
 in c-Src, 318  
 in E-cadherin, 328–329  
 in growth pathways, 273, 277t, 283  
 in p53, 210–211, 212f  
 biophysical details important, 212  
 in pRb-p53 and immortalization, 235–236  
 in PTEN, 302–303  
 and tyrosine kinase inhibitors, 293
- Myc, *see* c-Myc
- Myeloid-derived stromal cells, *see* Mesenchymal stem cells
- Myofibrils, 165
- N**
- NADPH oxidase complex  
 RacGTPase, regulation, 158–159, 159f  
 structure and function, 158–159, 158f, 159f  
 superoxide generation, 156–157, 157f
- N-CoR, 79, 79t
- Necrosis, 227–228
- Nectin-afadin system, 124, 124t
- Negative feedback  
 in  $\beta$ -oxidation, 30, 30f  
 in cell cycle regulation, 194–195, 195f

- in cholesterol uptake, 114
  - in CNS regulation of energy balance, 20
  - in the Goldbeter model, 192–194, 192f, 194f
  - in insulin signaling, 60
  - in leptin signaling, 38, 38f
  - in NO regulated NMDA receptor activity, 168–169, 378
  - in normal operation of A $\beta$ , 370, 374
  - Neurofibrillary tangles (NFT), 384, 386, 386f
  - Neuron, and disease, 12
  - Neuropeptide Y (NPY), 36–37, 37f
  - NF- $\kappa$ B signaling node
    - actions in the nucleus
      - co-activator complexes, 141–142, 141f
      - co-repressor complexes, 141–142, 141f
    - I $\kappa$ B proteins, 133–134, 133f
    - IKK proteins, 132, 134f
    - molecular components, 132, 134t
    - NF- $\kappa$ B proteins, 132–133, 132f
    - regulation by ubiquitination, 134
  - Nitric oxide
    - hemodynamic stimuli, vasodilation, 163
    - NOS enzymes, *see* NOS enzymes
    - as a signaling molecule, 155–156
    - by S-nitrosylation, 163
      - See also* S-nitrosylation
    - through pGC, 163, 166–167, 168f
  - Nitric oxide synthase, *see* NOS enzymes
  - N-linked glycan processing, 399–401, 400f
    - calnexin-calreticulin cycle, 399–401, 400f
    - oligosaccharyltransferase (OST) complex, 399–401
    - UGGT folding sensor, 400f, 401, 404
  - NMDA receptors
    - LTD in Alzheimer's disease, 378–379, 378f
    - regulation by NO (nNOS), 162–163, 381
    - UPS in Huntington's disease, 449
  - Non-exchangeable apolipoproteins, *see* Apolipoproteins
  - Nonhomologous end joining, 201, 215t, 218–220, 220f
  - NOS enzymes
    - eNOS, 162, 162f, 163
      - opposing actions by oxLDL, 113–114
      - regulation of blood flow (vascular tone), 112–113
    - iNOS, 143, 162, 162f
    - nNOS, 162, 162f, 168–169, 381
    - superoxide production, 163
  - Notch signaling
    - NICD transcription factor, 334
    - Notch processing, 333–335, 334f
    - role in metastasis, 333
    - transcriptional mechanisms, 335–336
  - Nox enzymes, 157–159, 158f, 159f, 161
  - Nuclear magnetic resonance (NMR), 7, 8
  - Nuclear receptors
    - classification, 71–72, 72t
    - corepressors and coactivators
      - activation and repression cycle, 79, 79f
      - binding motifs, 74, 79
      - transcriptional cofactors, 77–79, 79t
    - structure and function, 73–74, 73f
  - Nuclear reprogramming, 313
  - Nucleosome, 250, 250f
    - epigenetic marks, 251–252, 251f
    - histone tails, 251
  - Nucleotide excision repair (NER)
    - DNA damage, 201, 215t, 216
    - repair routes and enzymes, 216
- O**
- Oncogene addiction, 282–283
  - Oncogene-induced senescence (OIS)
    - by gene silencing, 241–243
    - by p53/p21 and pRb/E2Fs, 241–243
  - Oncogenic barriers, *see* Barriers, oncogenic
  - Oncomirs, 265
  - Orphan receptors, 71
  - Oxidative burst, 158
  - Oxysterols, 98
- P**
- p160 family, 79, 79t
  - p16Ink4a, in senescence, 237–238
  - p21, 185t
    - in p53-mediated senescence, 230t, 231
    - regulation by c-Myc and TGF $\beta$ , 325–326, 325f
  - p300/CBP, 79, 79t
  - p38 module, 275
  - p53 protein
    - in apoptosis, 233
    - mitochondrial actions, 233
    - transcriptional actions, 233
  - cancer-causing mutations, 211, 211f
  - in glucose starvation, 293
  - in regulation of glucose metabolism, 300
    - through oxidant and anti-oxidant production, 301–302
    - through SCO2, 301
    - through TIGAR, 300–301, 300f
  - restoration of function, 212
  - in senescence
    - core circuitry, 237–238, 238f

- p53 protein (*cont.*)  
 oncogene-induced, models, 237–240, 240f  
 posttranslational modifications, 240–241, 241f  
 replicative senescence, 236–237, 236f  
 structure and function, 210–212, 211f, 211f
- p66Shc, 301–302
- Paget, Stephen, 11, 338
- Paracellular diapedesis, *see* Diapedesis
- Paraventricular nucleus, 37
- Parkin  
 lewy bodies, 416  
 misfolded Pael-R, 416  
 regulation by S-nitrosylation, 170  
 structure and function, 413f, 416
- Parkinson's disease, 14t  
 disease progression, 437–438, 438f  
 mutated proteins, 412–413, 412t, 413f
- Pathogen-associated molecular patterns, 139
- Pattern recognition receptors, 139
- Paxillin, 318, 319  
 structure and function, 319f, 320
- PCAF/GCN5, 79t, 88f
- PDK1, 54–55, 55f
- PECAM-1 complexes, 124, 124t
- PERK signaling, 401, 402–403, 402f  
 ATF4 transcription factor, 402–403
- Peroxisome proliferator-activated receptor (PPAR) receptors, 72, 72t  
 isotypes and roles, 72, 75–76, 76f  
 regulation of metabolism in peripheral tissues, 75–77, 76f  
 structure and fatty acid binding, 77, 77f
- Peroxynitrite, 157
- Peroxynitrite, Alzheimer's disease, 382
- Perutz, Max, 7
- Phenotype plasticity, 313
- Phosphofructokinase 1, 2 (PFK1, 2), 49–50, 49f, 56f
- Phosphoinositide-3-OH kinase (PI3K)  
 class I PI3Ks, 52–54, 53f, 54f  
 class III PI3Ks in amino acid availability signaling, 293f, 296–298  
 class III PI3Ks in autophagosome activation, 299–300, 300f  
 in growth factor signaling, 272, 272f  
 phospholipid second messengers, 52–53
- PINK1  
 oxidative damage and apoptosis, 415  
 structure and function, 413f, 415
- Piwi-associated RNAs (piRNAs), 261
- Plant homeodomains (PHDs), 256, 257t
- Platelet-derived growth factor (PDGF) family, 273t, 275, 315t
- Plk1, 184, 185t
- Pocket proteins, 185–187  
*See also* pRb protein
- Polar zipper, 437
- Poly (ADP-ribose) polymerase (PARP), 382
- Polycomb group (PcG), 254, 254t  
 in iPSC cell maintenance, 266
- Polyglutamine repeat disorders, 14t, 346t, 347, 431, 432
- Polyglutamine tracts, 432
- Positive feedback  
 in  $\text{A}\beta$ -inflammation, 370  
 in  $\alpha$ -synuclein buildup and misfolding, 422  
 in AMPK and p53 circuits, 264, 293, 301  
 in cell cycle regulation, 194–195, 195f  
 in checkpoint pathways, 208  
 cytokine loops and inflammation, 48, 61–63, 61f  
 in MAP kinase modules, 278–279, 279f  
 oxLDL and NO, 114  
 ROS and protein kinase C, 66  
 in stabilizing healthy and disease states, 445
- Postsynaptic density, 377
- Pouletier de la Salle, 6
- PPAR $\gamma$  coactivator 1 (PGC-1), 79t  
 in caloric restriction, 86, 87–88, 88f  
 in catecholamine signaling, 85–86, 86f  
 in gluconeogenesis, 83–85, 84f  
 isoforms and structure, 80, 80f
- pRb protein  
 and E2Fs, 185–187, 186t, 186f  
 pRb-E2F node, in senescence  
 core circuitry, 237–238, 238f  
 in heterochromatin formation, 241–243, 243f  
 oncogene-induced, 241–243  
 replicative, 236–237, 236f
- Pregnane X/Steroid and xenobiotic receptors (PXR/SXR), 72, 72t
- Presenilins, 371, 372f
- Prion biophysics  
 Het-s, 359–360, 360f  
 strains and transmissibility  
 $\text{A}\beta$  protein, 361–362  
 apolipoprotein AII, 362  
 prions, 361  
 serum amyloid A, 362  
 Sup35, 359–360, 361f
- Prion diseases, 14, 14t, 358–359, 359t
- Pro-opiomelanocortin (POMC), 36–37, 36f

- Protein folding and finishing, 392–393, 396–398  
 anfinсен cage, 392  
 ER Stresses, 401  
 Golgi apparatus, 397–399, 398f  
 of membrane and secretory proteins, 397–401  
 N-linked glycan processing, *see* N-linked glycan processing  
 Protein folding physics, 345–346  
 cross- $\beta$  sheets, 362–364  
 energy landscapes, 349–352, 350f  
 fibrils, 362–364  
 folding funnels, *see* Energy Landscapes  
 native states  
   folded, 350  
   unstructured, unfolded, 352–354, 353f, 354f  
 thermodynamic hypothesis, 348–349  
 Protein kinase B signaling, *see* Akt/PKB  
 Protein kinase C  
 activation mechanism, 54–55, 55f  
 in growth factor signaling, 272, 272f  
 isozymes, 54–55, 54f  
 Protein kinase A signaling  
 in  $\beta$ -adrenergic receptor signal transduction, 28, 85–86, 86f  
 in glucagon signal transduction, 83–85, 84f  
 Protein misfolding, in disease, 67, 345, 421–422, 449  
*See also* Amyloid diseases; Mutations, cancer-causing  
 14–3-3 proteins  
 as a readout module, 252  
 regulation of Bad and FOXOs, 80–81, 80f, 81f  
 regulation of TORC2, 84f  
 structure and function, 82–83, 83f  
 Protein ubiquitination, 135–136, 135f  
 K48 ubiquitination, 136  
 K63 ubiquitination, 136  
 Prusiner, Stanley, 358  
 PTEN lipid phosphatase, 54, 54f  
 actions in the nucleus, 305  
 in cancer, 303, 304  
 regulation by oxidation, 303–304  
 structure and function, 303–304  
 Purcell, Edward, 8
- R**  
 Rabi, Isidor, 8  
 Rag GTPases, 296  
 Ramón y Cajal, Santiago, 12  
 Ramsey, Norman, 8  
 RANK/RANKL signaling pathway, 338–339  
 Ras GTPase, 272–273, 272f  
 activation mechanism, 276  
 adapters and signaling, 275–276  
 in cancer, 273  
 family members and structure, 273, 273f  
 Reaven, Gerald, 45  
 Receptor cooperativity, 316, 320–322, 321f  
 Receptor tyrosine kinases, 50, 272–274, 272f  
 in cancer, 272–273, 273t, 314, 315t  
 families and ligands, 276–277, 277t  
 receptor cooperativity, 320–322, 321f  
 signal transduction, 276–278  
 Regulated intramembrane processing (RIP), 96, 96f  
 in APP processing, 370–373, 372f  
 in Notch processing, 334–335, 334f  
 in SREBP processing, 96–97, 96f  
 Replication protein A, 208  
 Response to injury disease model, 5  
 Resveratrol, 87  
 Reverse cholesterol transport, 102–104, 104f  
 Rho GTPase, 275  
 RIP1 protein, 137f, 138, 139  
 Rittenberg, David, 6  
 Robert Weinberg, 180  
 Rodbell, Martin, 6, 9  
 Röntgen, William Conrad, 7  
 Rose, Irwin, 9  
 Ross, Russell, 5
- S**  
 S6K protein, 295  
 Salt-inducible kinases (SIKs), 83–85, 84f  
 Sanger, Frederick, 348  
 SANT domain, 258  
 Sarcomeres, 165  
 SCF complexes, 184, 185t, 189, 196–197  
 F-box proteins, 189  
 in regulation of c-Myc, 286  
 structure and function, 190–191, 190f  
 Schleiden, Mathias, 13  
 Scrapie, *see* Prion diseases  
 Second-site suppressors, 212  
 Secretin, 4  
 Seed-and-soil hypothesis, 11, 338–339  
 Selectins  
 role of slip and catch bonds, 119–121, 121f  
 in tethering and rolling, 118–119, 119f  
 types and expression, 115, 115t  
 Senescence, 232  
 heterochromatin formation, 241–243, 243t

- Senescence (*cont.*)  
 inflammatory second signals, 240  
 Ink4a/ARF locus, 237–238  
 oncogene induced, models, 237–240, 240f  
 regulation by p53 and pRb, 236–237, 236f  
 replicative, 236–237
- Serpinopathies, 347t, 348
- Serpins, metastable states, 357–358
- Sestrins, 161, 161f, 169
- Shear stresses, 109–110  
 physiological correlates, 111, 111t  
 regions of low values, 110–111, 111f  
 shear stress responsive elements, 112
- Sherrington, Arthur, 12
- Short interfering RNAs (siRNAs), 260, 260f
- Signaling networks, Outside-in and inside-out  
 maintains health, 179–180, 180f  
 roles of positive feedback, 449  
*See also* Negative feedback; Positive feedback  
 stabilizes disease states, 446–448, 447f
- Sirtuins, 86–87, 87t  
 Sir2, 249, 249t  
 SIRT1-mediated fatty acid oxidation,  
 87–88, 88f
- Skeletal muscle fibers  
 fast twitch, 167  
 fatty acid utilization, 166  
 metabolic programs, 166–167  
 slow twitch, 167
- Slicer, *see* Argonaute proteins
- Sliding clamp, MutS, 218
- Slip bonds, 119–121, 121f
- Small noncoding RNAs, 260
- Smooth muscle cells, in the arterial wall, 108f
- SMRT, 79, 79t
- S-nitrosylation, 168–170  
 feedback regulation of NOS enzymes, 170  
 NMDA receptors and excitotoxicity, 169  
 parkin, 169  
 Pdi, 169
- SOCS3, negative regulation by, 38, 38f
- Somatostatin, Secretion by  $\delta$ -cells, 21t
- Son of sevenless (Sos) proteins, 275, 277
- Spinal and bulbar muscular atrophy (SBMA),  
 432t, 433
- Spino-cerebellar ataxia 1, 432t, 433
- Spino-cerebellar ataxia 3, 432–433
- Spongiform encephalopathies, *see* Prion diseases
- 26S proteasome, *see* Ubiquitin-proteasome system
- Src, *see* c-Src
- SREBPs  
 cooperate with LXRs and FXRs, 97  
 family members, 95–97  
 processing, RIP, 96, 96f  
 Scap and Insig1, 96, 96f  
 transcriptional targets, 97–98
- ssDNA-associated chromatin subcompartments  
 (SDSCs), 203, 204f
- Stein, William, 348
- Stellate cells, *see* Hepatic stellate cells
- Stem cells, 11
- Stem cells, *see* Mesenchymal stem cells  
*See also* Cancer stem cells; Induced pluripotent stem (iPS) cells
- Stern, Otto, 8
- Stroke volume, 164, 164f
- Stromal vascular fraction, 145
- SUMO proteins, 143, 144f  
 E1, E2 and E3 enzymes, 143  
 transrepression of TLR4 signaling,  
 144–145, 144f
- Superoxide dismutase 1 (SOD1), 156–157,  
 157f, 431–432  
 mutations and aggregation, 441–442  
 Nox regulation, 445–446, 446f  
 structure and function, 440, 441f
- Superoxide production, 156, 157–158, 157f,  
 167
- Sustained angiogenesis, in cancer, 181–182,  
 181f
- Sutherland, E. W., 8
- Syndrome X, 45
- T**
- Target-based anti-cancer therapies, 283–284
- Taupathies, 384
- Tau protein, 384–385, 385t  
 hyperphosphorylation, 384–385, 385f  
 neurofibrillary tangles, 384, 385f  
 structure and function, 393, 394f  
 synergism with A $\beta$ , 386
- TDP-43 protein, 448
- TDP-43 proteinopathies, 448
- Telomerase, 235–236
- Telomeres  
 capping proteins, 234, 235t  
 hayflick limit, 234  
 immortalization, 235  
 structure, 234–235, 242t
- Theisch, Carl, 10–11
- Thioredoxin peroxidase (Prx), 160, 161f
- Thioredoxin system, 161, 161f
- Tight junctions, 123–124, 124t

- Tissue remodeling, 11
- Toll-like receptor 4 signaling  
 LPS, 143, 144  
 mammalian lipids, 139–140, 140f  
 signaling through TIRAP and Myd88, 140, 140f  
 signaling through TRAM, 140, 140f  
 transrepression, 143–145, 144f
- Toll-like receptors, TLRs, In Alzheimer's disease, 380–382
- Toll pathway, *see* IL-1/Toll signaling pathway
- TOR complexes (TORCs), 59–60, 59f  
 feedback regulation of Akt, 60  
 raptor and rictor, 59–60, 59f
- TRAF adapters, 137–138
- Transcellular diapedesis, *see* Diapedesis
- Transdifferentiation, 266
- Transducer of regulated CREB activity 2 (TORC2), 83–85, 84f
- Transforming growth factor- $\beta$  (TGF- $\beta$ ) pathway, 322–325  
 in bone metastasis, 338  
 cytostasis program  
 regulation of cell cycle inhibitors, 325–326, 325f  
 regulation of c-Myc, 325, 325f  
 and myofibroblasts, 149  
 pathway components and branches, 322–323, 323t  
 role in the EMT, 329f, 330  
 Smad proteins, 323t, 325f, 328–329
- Translation initiation  
 assembly of the complex, 288–290, 288f  
 eIF2B and 4E-BP1 control points, 295–296  
 initiation factors, 296, 297t  
 regulation by mTOR, 292–293, 295–296
- Transmissible spongiform encephalopathies, *see* Prion diseases
- Transrepression  
 by Glucocorticoids, 142–143, 145  
 by LXRs and PPAR $\gamma$ , 143–144  
 of TLR4 signaling, 144–145, 144f
- TriC/CCT chaperones, *see* Chaperonins
- TriC, and mutant HTT, 437
- Trithorax (trx), 254, 254t
- Tuberous sclerosis complex  
 function as a Rheb GAP, 58–59, 59f  
 structure, 58, 59f
- Tudor domains, 256, 257t
- Tumor growth and metastasis  
 disease progression, 179–180, 180f  
 hallmarks of cancer, 180–181, 180f
- Tumor necrosis factor  $\alpha$  pathway, 131  
 in the brain, 373–374, 373f  
 cleavage by TACE, 137  
 complex I, 137–138, 137f  
 complex II, 137f, 138  
 in insulin resistance, 60–63, 61f
- Tumor stroma, 181–182, 181f, 182f, 283
- Type 1 diabetes, 4, 45
- Type 2 diabetes, 3, 45  
 disease progression, 46–47, 47f  
 insulin resistance, *see* Insulin resistance  
 leptin resistance, 62–63
- Tyrosine kinase inhibitors (TKIs), 283
- U**
- Ubiquitin, 135, 144f
- Ubiquitination, *see* Protein ubiquitination
- Ubiquitin-proteasome system, 135, 381, 391, 407, 421–422, 423f, 439
- UCH-L1  
 20S proteasome, 417  
 protein carbonylation, 417  
 structure and function, 413f, 417
- Ultrasensitivity, 280, 281f
- Unfolded protein response (UPR), 391–397  
 ATF6 signaling, *see* ATF6 signaling  
 BiP ER chaperone, 394  
 IRE1 signaling, *see* IRE1 signaling  
 PERK signaling, *see* PERK signaling  
 sensing of low oxygen conditions, 293
- Unstable repeat disorders, *see* Polyglutamine repeat disorders
- Urokinase-type plasminogen activator (uPA), 316, 321f, 322
- V**
- Vascular endothelial growth factor (VEGF)  
 family, 273t, 274–275, 322
- Vascular tone, 167–168, 168f
- Very low density lipoproteins (VLDLs), 99, 100t, 100, 103
- Virchow, Rudolf  
 amyloids, 12–13  
 atherosclerosis, 5, 6  
 inflammation, 4
- Voltage-dependent anion channel, 307–308, 308f
- Von Laue, Max, 7
- W**
- Waddington, Conrad, 249
- Waldeger, Wilhelm, 11
- Warburg, Otto, 10, 291

- Ward, Colin, 8  
Wee1, 185t  
Weinberg, Robert, 10  
Weinstein, Bernard, 282  
Weismann, August, 234  
Wieland, Heinrich, 6  
Wiener, Norbert, 20  
Windaus, Adolf, 6  
Wnt pathway  
    pathway components and branches,  
        317–318  
    role in the EMT, 322–325  
    TCf/LEF gene expression, 327, 327f  
    Wnt destruction complex, 326, 326f  
Wütrich, Kurt, 8
- X**  
Xanthine oxidoreductase, 167  
X-ray crystallography, 7–8
- Z**  
Zonula occludens (ZO) proteins, 123, 124t